[go: up one dir, main page]

BRPI0916597A2 - Método - Google Patents

Método

Info

Publication number
BRPI0916597A2
BRPI0916597A2 BRPI0916597-5A BRPI0916597A BRPI0916597A2 BR PI0916597 A2 BRPI0916597 A2 BR PI0916597A2 BR PI0916597 A BRPI0916597 A BR PI0916597A BR PI0916597 A2 BRPI0916597 A2 BR PI0916597A2
Authority
BR
Brazil
Application number
BRPI0916597-5A
Other languages
English (en)
Inventor
Geoffrey Duke Edward Clarke
Timothy James Grattan
Ian Burnett
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of BRPI0916597A2 publication Critical patent/BRPI0916597A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0916597-5A 2008-07-30 2009-07-29 Método BRPI0916597A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0813929.7A GB0813929D0 (en) 2008-07-30 2008-07-30 Novel method
PCT/US2009/052039 WO2010014661A1 (en) 2008-07-30 2009-07-29 Novel method

Publications (1)

Publication Number Publication Date
BRPI0916597A2 true BRPI0916597A2 (pt) 2015-08-04

Family

ID=39747175

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0916597-5A BRPI0916597A2 (pt) 2008-07-30 2009-07-29 Método

Country Status (12)

Country Link
US (2) US8604084B2 (pt)
EP (1) EP2309852A4 (pt)
CN (1) CN102170782A (pt)
AU (1) AU2009276664B2 (pt)
BR (1) BRPI0916597A2 (pt)
CO (1) CO6341514A2 (pt)
GB (1) GB0813929D0 (pt)
MX (1) MX2011001124A (pt)
MY (1) MY151230A (pt)
NZ (1) NZ591408A (pt)
RU (1) RU2517139C2 (pt)
WO (1) WO2010014661A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3210597A1 (en) 2010-09-13 2017-08-30 Bev-RX, Inc. Aqueous drug delivery system comprising off- flavor masking agent
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
GB202007670D0 (en) * 2020-05-22 2020-07-08 Glaxosmithkline Consumer Healthcare Holdings Us Llc Pharmaceutical composition
CN115444823B (zh) * 2022-10-12 2024-02-23 苏州中化药品工业有限公司 一种含瑞巴派特颗粒及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1182049A (en) * 1981-07-13 1985-02-05 Francis J. Sterbenz Apap antacid composition
US6264983B1 (en) * 1999-09-16 2001-07-24 Rhodia, Inc. Directly compressible, ultra fine acetaminophen compositions and process for producing same
GB0114069D0 (en) * 2001-06-08 2001-08-01 Smithkline Beecham Plc Composition
EP1536841A1 (en) * 2002-09-12 2005-06-08 The University of Chicago Monitoring and diagnosis of gastric emptying and gastroparesis
US20050108021A1 (en) 2003-07-31 2005-05-19 Greg Anderson System and method for routing and managing service requests
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
US20070298096A1 (en) * 2004-10-28 2007-12-27 Rong Liu Analgesic/Antipyretic Compositions for Enhanced Absorption
GB0607085D0 (en) * 2006-04-07 2006-05-17 Smithkline Beecham Corp Novel compositions
US7863275B2 (en) * 2006-10-30 2011-01-04 The Board Of Regents Of The University Of Texas System Uses of tetrahydrobiopterin and derivatives thereof

Also Published As

Publication number Publication date
US8604084B2 (en) 2013-12-10
NZ591408A (en) 2012-12-21
AU2009276664A1 (en) 2010-02-04
WO2010014661A1 (en) 2010-02-04
RU2011107285A (ru) 2012-09-10
GB0813929D0 (en) 2008-09-03
US20110301243A1 (en) 2011-12-08
AU2009276664B2 (en) 2013-02-07
EP2309852A1 (en) 2011-04-20
MY151230A (en) 2014-04-30
EP2309852A4 (en) 2011-08-24
CN102170782A (zh) 2011-08-31
US20140066516A1 (en) 2014-03-06
MX2011001124A (es) 2011-03-29
RU2517139C2 (ru) 2014-05-27
CO6341514A2 (es) 2011-11-21

Similar Documents

Publication Publication Date Title
BRPI0919116A2 (pt) método
BRPI0814359A2 (pt) Método
BRPI0817226A2 (pt) Método
BRPI0817726A2 (pt) Método
BR112012004707A2 (pt) método
BR112012000624A2 (pt) método
FI20090389A0 (fi) Menetelmä
DK2313489T3 (da) Fremstillingsmetode
DK2342317T3 (da) Hængende-dråbe-plade
BRPI0906764A2 (pt) Processos
DE602009000234D1 (de) msignals
BRPI0907376A2 (pt) Fotobiorretador
BRPI0914649A2 (pt) Piprazolo-quinazolinas
DE602008003972D1 (de) Sitzrücklehnungsmechanismus
DE602008003521D1 (de) Sitzrücklehnungsmechanismus
DK2335031T3 (da) In-line-måler
DK2336132T3 (da) Morpholinpurinderivat
BRPI1012526A2 (pt) método
BRPI0911625A2 (pt) Métodos
BRPI1010705A2 (pt) método
DK2271613T3 (da) Hydroxymethylcyklohexylaminer
DE602008003970D1 (de) Strahlstromkalibriersystem
BRPI0907522A2 (pt) biarlamidas
BRPI1012532A2 (pt) método
DE112009000183A5 (de) Sicherheitsvorreiber

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2473 DE 29-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.